Johnson & Johnson (JNJ) Earnings Date & Reports

Johnson & Johnson delivered robust Q1 2026 results, with worldwide sales of $24.1 billion, reflecting 9.9% reported growth, 6.4% operational growth (excluding currency), and 5.3% adjusted operational growth (also excluding acquisitions/divestitures). This topped consensus estimates of approximately $23.6 billion.

GAAP diluted EPS was $2.14, down from $4.54 year-over-year due to special items including litigation and in-process R&D (research and development) impairments. Adjusted diluted EPS of $2.70 exceeded expectations of $2.68 and adjusted net earnings reached $6.6 billion, down slightly from $6.7 billion in the prior year.

Innovative Medicine sales hit $15.4 billion (7.4% operational growth), fueled by Darzalex ($4.0 billion, beating estimates), Tremfya ($1.6 billion), and newer assets like CARVYKTI, offset by Stelara's sharp decline to $656 million (down ~60% due to biosimilars). MedTech posted $8.6 billion (4.6% operational), driven by electrophysiology, Abiomed, and Shockwave. U.S. sales grew 8.3% to $13.3 billion; international rose 3.9% operationally to $10.7 billion.

Guidance was raised: full-year reported sales $100.3-$101.3 billion (midpoint $100.8 billion, 7.0% growth); adjusted operational EPS $11.30-$11.50 (midpoint $11.40, up from prior view).

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis of stocks like JNJ.

Market Reaction and Investor Sentiment

Following the April 14 release, JNJ shares initially dipped in premarket trading amid scrutiny of the modest guidance raise and ongoing Stelara pressures but recovered, closing up about 0.9% at around $240. Sentiment remains cautiously optimistic, with analysts noting the earnings beat and raised outlook as validation of ex-Stelara double-digit growth potential. However, some highlighted conservative full-year projections relative to the stock's year-to-date gains of 15%, tempering enthusiasm.

Forward Outlook and Key Factors to Monitor

Johnson & Johnson's raised 2026 guidance signals confidence in hitting $100 billion in sales, driven by Innovative Medicine's oncology momentum (Darzalex, RYBREVANT) and immunology offsets via Tremfya and new launches like ICOTYDE for psoriasis. MedTech's cardiovascular expansion, including VARIPULSE Pro in Europe, supports steady growth.

Investors should watch Stelara biosimilar erosion, now at a 540 basis point headwind company-wide, and mitigation through pipeline catalysts like nipocalimab for systemic lupus erythematosus (SLE) and TECVAYLI combinations. Manufacturing investments, such as over $1 billion in cell therapy capacity, aim to scale CARVYKTI and similar assets.

Cost trends, including intangible amortization and R&D spend ($3.5 billion in Q1), alongside free cash flow generation (~$1.5 billion quarterly), will influence capital allocation: dividends (now $1.34 quarterly), share repurchases, and M&A (mergers and acquisitions). The planned December 8 Enterprise Business Review may outline strategic shifts. Broader dynamics like currency (euro at 1.17) and most-favored-nation pricing policies bear monitoring for margin impacts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations